USEFUL RESOURCES

Downloadable Resources

Video Resources

Dr. Viola W. Zhu offers her perspective on treating firstline ALK+ mNSCLC and reviews the first-line ALUNBRIG clinical data Dr. Viola W. Zhu offers her perspective on treating firstline ALK+ mNSCLC and reviews the first-line ALUNBRIG clinical data

Talking ALK-Positive Opinions

Dr. Viola W. Zhu provides her perspective on treating patients with ALK+ mNSCLC in the front line and reviews the first-line clinical data for ALUNBRIG.

Watch the Webcast
Dr. Alex Spira of the Virginia Cancer Specialists Research Institute discusses ALUNBRIG for ALK+ mNSCLC on ONCLive Dr. Alex Spira of the Virginia Cancer Specialists Research Institute discusses ALUNBRIG for ALK+ mNSCLC on ONCLive

Exploring Key Safety and Patient Data

Dr. Alex Spira, Director of the Virginia Cancer Specialists Research Institute, discusses ALUNBRIG for the treatment of adult patients with ALK+ mNSCLC.

Watch the Webcast

Stay Connected

Register to receive useful information and updates about ALUNBRIG.

Register Now!

 

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib) and entering one that is not owned or controlled by Takeda Oncology.

Takeda Oncology makes no representation as to the accuracy of the information contained on sites we do not own or control. Takeda Oncology does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Cancel Continue +

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib) and entering one that is not owned or controlled by Takeda Oncology.

This link will take you to the corporate ARIAD Pharmaceuticals, Inc. website.

Cancel Continue
Close

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib).

This link will take you to another Takeda Oncology website.

Cancel Continue +

The site you are about to enter is intended for US healthcare professionals only.

Please confirm that you are a US healthcare professional.

Yes, I confirm that I am a US healthcare professional Cancel +

In Vitro: ALUNBRIG Inhibited 17
ALK-Inhibitor—Resistant Mutations1,2

ALUNBRIG exhibited in vivo antitumor activity against 4 mutant forms of EML4-ALK, including the G1202R and L1196M mutants identified in NSCLC tumors in patients who had progressed on crizotinib.


 
 

We use cookies to gather web statistics that help us improve our site. We store no personal details.
ACCEPT

Read More